Xavier Farde is reputed for his advice on leveraged and acquisition finance matters. One impressed source describes him as a "very strong and very experienced" lawyer.Chambers Europe 2019

Xavier Farde

Paris
  • 45, rue Saint-Dominique
  • Paris 75007
  • France
 
 

Xavier Farde is the Office Managing Partner of Latham & Watkins’ Paris office. Mr. Farde has extensive experience in senior and mezzanine debt finance for leveraged acquisitions, as well as in banking and syndicated loans, involving the healthcare, technology, and retail industries. He also advises on real estate finance. He practices in the field of bank finance representing both lenders and borrowers in a wide range of domestic and cross-border financing and restructuring transactions.

Recognitions

Mr. Farde is recognized as a Leading Individual by Legal 500 EMEA 2019.

“Interviewees single Xavier Farde out as being ‘a leader in the market.’ […]. Sources further enthuse: ‘He is technically prepared and commercially smart.’”
Chambers France 2018

“Xavier Farde receives outstanding client feedback: ‘an excellent practitioner with strong commercial skills.’” Chambers Global 2017

Mr. Farde’s experience includes representing:

  • The lead arrangers in a €900 million financing of Financière Colisée
  • The mandated lead arrangers in the refinancing of the existing financial indebtedness of the Ceva Group, a veterinary pharmaceutical laboratory, for a total amount of €2.150 billion   
  • HLD Europe in connection with the financing of the acquisition of Kiloutou
  • The banks in connection with the financing of the acquisition of Ibersnacks and Agromaiz, producers and suppliers of snacks in France and Spain, by Apax Partners
  • Altran Technologies in connection with the financing of the acquisition of Aricent Technologies
  • Unither Pharmaceuticals a France-based pharmaceutical manufacturing company in connection with the refinance existing debt
  • Eurazeo Capital in connection with the financing of the acquisition of Dutch Ophthalmic Research Center (DORC), a medical technology company from Montagu
  • Assystem Technologies in connection with the financing of the acquisition of SQS Software Quality Systems
  • Ardian in connection with the financing of the acquisition of 100% equity stake in Les Dérivés Résiniques et Terpéniques
  • ICG in connection with the refinancing of Domus VI
  • Partners Group in connection with the financing of the acquisition of Foncia
  • Bridgepoint in connection with the financing of the acquisition of Calypso
  • BNPP and HSBC in connection with the financing of the acquisition of Meilleurs Taux
  • Ardian in connection with the financing of the acquisition of DRT
  • Ardian in connection with the financing of the acquisition of Grand Frais
  • Crédit Agricole CIB, CIC, ING, Natixis, and Bank of Ireland in connection with the refinancing of Colisée International
  • Ardian in connection with the financing of the acquisition of Trigo Group
  • BNP Paribas and J.P. Morgan in connection with the financing of the acquisition of Infropro Digital by Towerbrook
  • Ardian in connection with the financing of the acquisition of Hypred

 
 
 
Notice: We appreciate your interest in Latham & Watkins. If your inquiry relates to a legal matter and you are not already a current client of the firm, please do not transmit any confidential information to us. Before taking on a representation, we must determine whether we are in a position to assist you and agree on the terms and conditions of engagement with you. Until we have completed such steps, we will not be deemed to have a lawyer-client relationship with you, and will have no duty to keep confidential the information we receive from you. Thank you for your understanding.